BRAIN Biotech announces 3M 25/26 results and breakthrough at BioIncubator company SolasCure
February 25, 2026 – Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical – BRAIN Biotech, biosolutions, chronic wounds, enzymes, life sciences, microbial production strains
- Aurase Wound Gel showing strong clinical evidence of superior debridement and healing in chronic wounds
- Aurase shows dual action on chronic wound debridement and healing
- SolasCure preparing fund raising for clinical phase 2b/3
- Sequential growth forecasted in the next quarters for BRAINBiocatalysts.
25 February 2026 — Zwingenberg, Germany — BRAIN Biotech AG, a leading provider of specialty enzymes and innovative biosolutions for industry, has published its financial figures for the first three months of the fiscal year 2025/26.
BRAIN Biotech Group generated Q1 revenue of € 11.9 million compared to € 13.1 million in the same period of the previous year, a decrease of 9.0 %. The group strongly improved the adjusted EBITDA to € 0.3 million from € -0.7 million in the same period last year, reflecting the strong performance of the BRAINBioIncubator segment. The BRAINBioIncubator segment benefitted from a milestone income of € 1.0 million from the deucrictibant program. The core segment BRAINBiocatalysts had the expected slow start to the year but is forecasted to show sequential growth over the next quarters.
The company today announced very positive news on its BRAINBioIncubator participation SolasCure. SolasCure is an independent clinical development company in which BRAIN Biotech holds a 35 % stake and additional production rights to the active pharmaceutical ingredient (API) tarumase. SolasCure has now successfully completed an extension study of Phase 2a clinical development. The treatment of chronic wounds with Aurase® Wound Gel which combines a hydrogel with the enzymatic active ingredient tarumase shows both a 22 times more effective wound debridement and a 7 times accelerated healing compared to the current standard of care in the control group. SolasCure sees a total addressable market for the advanced treatment of chronic wounds of around US$ 4.3 billion in the US alone.
With this positive clinical data, SolasCure is now seeking a larger financing round to secure funding for the next steps in clinical development. Adriaan Moelker, CEO BRAIN Biotech, comments: “I am really thrilled by the clinical data the SolasCure team has been able to demonstrate. There is a large global need for innovation in advanced wound care. Aurase Wound Gel has demonstrated to accelerate wound debridement and healing at the same time and has therefore the potential to become a best-in-class first line treatment for chronic wounds with a large addressable market. We at BRAIN Biotech are very proud to have invented this enzyme and to be an active partner in its commercialization.”
About BRAIN Biotech
The BRAIN Biotech Group is a leader in researching, developing, and producing specialty enzymes, focusing on the food and life sciences industries. In addition, the group develops microbial production strains and scalable bioprocesses for the economic production of specialty enzymes and other proteins. BRAIN Biotech also offers customized biological solutions to the industry for more sustainable products and efficient processes. BRAIN Biotech AG is the parent company of the BRAIN Biotech Group. The company´s activities are divided into two business segments: BRAINBiocatalysts (development, production, and distribution of specialty enzymes, microorganisms, and ingredients) and BRAINBioIncubator (research-intensive development projects and pharmaceuticals). BRAIN Biotech operates its own fermentation facilities in the UK and has additional production sites in continental Europe and the US. In the 2024/25 fiscal year, the group generated revenue of € 49.6 million with around 280 employees. Visit: brain-biotech-group.com/en.
